Physician profile
Nubia Lomeli
NPI 1619328374
$5,503.73
in general payments reported to CMS, 2019-2025
26 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $368 · 2022: $1,549 · 2023: $1,030 · 2024: $1,292 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,587.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,832.71 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $596.87 | 2021-2025 | |
| Novo Nordisk INC | $450.07 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $332.97 | 2021-2025 | Aveir, Assurity, Freestyle Libre 3 |
| Lilly USA, LLC | $307.03 | 2022-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $251.52 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $231.88 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $188.69 | 2022 | |
| Amgen INC. | $172.06 | 2024-2025 | Otezla, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $156.38 | 2024-2025 | Rexulti |
| Pfizer INC. | $153.17 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.96 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $131.02 | 2022-2024 | Watchman Flx |
| Glaxosmithkline, LLC. | $115.30 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lundbeck LLC | $60.34 | 2024-2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $59.53 | 2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $49.90 | 2021-2022 | |
| Shield Therapeutics INC | $42.45 | 2023-2024 | |
| Amarin Pharma, INC. | $42.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $42.06 | 2021-2022 | |
| Seqirus USA INC | $28.95 | 2024-2025 | Fluad, Flucelvax |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.20 | 2025 | Lifevest |
| Biohaven Pharmaceuticals, INC. | $23.53 | 2021 | |
| Intra-Sana Laboratories | $22.28 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Ironwood Pharmaceuticals, INC | $21.97 | 2024 | |
| Recordati_rare_diseases_inc. | $19.56 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nubia Lomeli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.